Company description

Nanopharm, an Aptar Pharma Company, is a world leading specialist contract research organization (CRO) offering product design and development services for orally inhaled and nasal drug products (OINDPs). Nanopharm operates a fee-for-service model, helping its clients navigate the scientific, technical and regulatory challenges in developing nasal and respiratory drug products from discovery through to clinical investigations (‘IND’). Its service offerings provide the most efficient path to success for its clients by providing an integrated drug development service covering:

• Advanced materials characterization

• Device and formulation development

• Inhaled biopharmaceutics

 These early phase services aid successful product development by understanding how material properties and processing conditions influence product functionality and therefore reduce risks and expedite drug development timelines.

 The technology platforms for advanced materials characterization, formulation & device development and in-silico modelling of in vivo behavior, have provided Nanopharm a technical competitive edge, helping it become an international market leader. For more information visit:


Quick facts

Sales markets Western Europe; Eastern Europe; Middle East; Asia; Australia; North America; Africa; Central/South America
Affiliated categories: Contract Services - Analytical & Lab Services |Contract Services - Contract Services |Contract Services - Pre Clinical Trials, Clinical Trials Stages 1-4, CRO, Clinical Data More

Recently at

5 nov 2019

CPhI Worldwide 2019

5-7 November 2019 Frankfurt, Germany We were at stand 111D70 See our Exhibitor Profile   See full Exhibitor List

Contact information




View all contact information